Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Gold Miners ETF (GDX) vs Eli Lilly And Co (LLY) Price & Performance

VanEck Gold Miners ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

VanEck Gold Miners ETF vs Eli Lilly And Co — how do they compare? VanEck Gold Miners ETF trades at $90.89, while Eli Lilly And Co trades at $1,216.42 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals.

GDXLLY
52-Week High
$115.84$1.24K
52-Week Low
$56.60$639.43
Market Cap
$1.08T
Sector
Health
Enterprise Value
$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Gold Miners ETF

GDX, the VanEck Gold Miners ETF, trades at $91.15, up 0.73% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights institutional repositioning and strong gold price momentum driving miner performance. The ETF provides diversified exposure to gold mining equities amid a seven-week gold rally near $4,300 per ounce.

Outlook is positive given gold's strength, but risks include volatility from Fed policy shifts and miner underperformance versus bullion. Analyst sentiment is mixed, with some advocating for value while others caution on stretched valuations. Upside depends on sustained gold prices and mining operational efficiency.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About VanEck Gold Miners ETF

The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.

Read more on GDX

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY